A recent study of knowledge, attitudes, and beliefs reported that fewer than half of adults are aware of RSV, despite the adults in the study being at increased risk of severe RSV disease due to age or underlying comorbidity such as cardiopulmonary disease or diabetes.1
On behalf of GSK and our panel of key experts, we hope you were able to join us for the RSV Learning Lounge Navigating RSV in Adults: Insights into Disease and Vaccination during the recent ATS International Conference in San Diego, CA.
In this session, experts delved into the wide-ranging topic of Respiratory Syncytial Virus (RSV) in adults. This session explored the true burden of RSV disease in adults, risk factors for severe disease in your patient population, and public health implications of RSV. The panel experts also discussed innovative social and digital tactics to improve respiratory health literacy and considerations for RSV vaccine implementation in the adult population following the ACIP’s recommendation that adults aged ≥60 years may receive a single dose of an RSV vaccine using shared clinical decision-making.2
We hope this discussion improves your clinical understanding of RSV disease burden in your relevant patient populations to support shared clinical decision-making conversations with your patients.
GSK works with top specialists to keep up with research and educate HCPs and patients about RSV.
To access additional information on RSV in adults after the conference, please visit the GSK US Medical Affairs Portal where you can access tools and resources such as videos and infographics to support your clinical understanding of RSV and to improve patient disease awareness and understanding of risk.
Sincerely,
GSK US Medical Affairs Team
Reference:
- La EM, et al. Hum Vaccin Immunother. Published online January 31, 2024. doi:10.1080/21645515.2024.2303796.
- Melgar M, et al. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. Accessed April 5, 2024. http://dx.doi.org/10.15585/mmwr.mm7229a4.
PSE-US-2595